Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes.

John J. Park,Keun-Wook Lee,Do-Youn Oh,Dhanusha Sabanathan,Se-Hyun Kim,Tae Min Kim,Myung-Suk Kim,Jaebong Yoon,H. Lee,Boram Kim,Ko Yunjung,Eunyoung Jeon,Seonghye Cheon,Eunyoung Shim,Bum-Chan Park,Han-Seung Lee,Seongyeol Park,Kyunghyun Paeng,Chan-Young Ock

Interim analysis of first-in-human phase 1 study to assess safety and efficacy of YBL-006, an anti-PD-1 antibody in advanced solid tumor with exploratory biomarker analysis of tumor mutational burden and artificial intelligence (AI)-powered spatial analysis of tumor-infiltrating lymphocytes.

2021

John J. Park
Keun-Wook Lee
Do-Youn Oh
Dhanusha Sabanathan
Se-Hyun Kim
Tae Min Kim
Myung-Suk Kim
Jaebong Yoon
H. Lee
Boram Kim
Ko Yunjung
Eunyoung Jeon
Seonghye Cheon
Eunyoung Shim
Bum-Chan Park
Han-Seung Lee
Seongyeol Park
Kyunghyun Paeng
Chan-Young Ock

e14552Background: YBL-006 is an anti-programmed death-1 (PD-1) antibody with a higher affinity compared to that of other PD-1 antibodies, which showed a favorable safety profile in animal models. W...

Keywords:

Advanced Solid Tumor
Medicine
safety profile
Biomarker Analysis
first in human
Tumor-infiltrating lymphocytes
Cancer research
Interim analysis
Antibody
anti pd 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations